Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms.
DUP
cannabis
dissociation
first-episode psychosis
schizophrenia
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
30 11 2021
30 11 2021
Historique:
received:
10
10
2021
revised:
25
11
2021
accepted:
27
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The Duration of Untreated Psychosis (DUP) is the time between the first-episode psychosis (FEP) and the initiation of antipsychotic treatment. It is an important predictor of several disease-related outcomes in psychotic disorders. The aim of this manuscript is investigating the influence of cannabis on the DUP and its clinical correlates. During years 2014-2019, sixty-two FEP patients with and without cannabis use disorder (CUD) were recruited from several Italian psychiatric hospitals. The subjects were then divided into two groups based on the duration of the DUP and assessed at the beginning of the antipsychotic treatment and after 3 and 6 months, using the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF) scale, and the Dissociative Experiences Scale (DES-II). As expected, a longer DUP was associated with worse symptoms and cannabis use did not seem to affect the DUP, but both were related with more dissociative symptoms at onset and over time. According to our study, cannabis use can be a predictor of FEP and DUP, and of disease outcome. However, several factors might influence the relationship between cannabis use and DUP. Preventing cannabis use and early diagnosis of psychotic disorders might impact the disease by reducing the persistence of symptoms and limiting dissociative experiences.
Sections du résumé
BACKGROUND
The Duration of Untreated Psychosis (DUP) is the time between the first-episode psychosis (FEP) and the initiation of antipsychotic treatment. It is an important predictor of several disease-related outcomes in psychotic disorders. The aim of this manuscript is investigating the influence of cannabis on the DUP and its clinical correlates.
METHODS
During years 2014-2019, sixty-two FEP patients with and without cannabis use disorder (CUD) were recruited from several Italian psychiatric hospitals. The subjects were then divided into two groups based on the duration of the DUP and assessed at the beginning of the antipsychotic treatment and after 3 and 6 months, using the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF) scale, and the Dissociative Experiences Scale (DES-II).
RESULTS
As expected, a longer DUP was associated with worse symptoms and cannabis use did not seem to affect the DUP, but both were related with more dissociative symptoms at onset and over time.
DISCUSSION
According to our study, cannabis use can be a predictor of FEP and DUP, and of disease outcome. However, several factors might influence the relationship between cannabis use and DUP. Preventing cannabis use and early diagnosis of psychotic disorders might impact the disease by reducing the persistence of symptoms and limiting dissociative experiences.
Identifiants
pubmed: 34886357
pii: ijerph182312632
doi: 10.3390/ijerph182312632
pmc: PMC8657003
pii:
doi:
Substances chimiques
Antipsychotic Agents
0
Hallucinogens
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Références
Drug Alcohol Depend. 2021 Sep 1;226:108873
pubmed: 34275699
Curr Pharm Des. 2014;20(13):2186-93
pubmed: 23829363
Eur Neuropsychopharmacol. 2020 Mar;32:131-135
pubmed: 32037127
Schizophr Bull. 2020 Mar 18;:
pubmed: 32251520
Int J Soc Psychiatry. 2018 Nov;64(7):690-704
pubmed: 30442059
J Nerv Ment Dis. 1986 Dec;174(12):727-35
pubmed: 3783140
Neuropsychopharmacology. 2017 Oct;42(11):2214-2221
pubmed: 28294137
Psychol Med. 2016 Nov;46(15):3127-3136
pubmed: 27534999
World Psychiatry. 2016 Oct;15(3):195-204
pubmed: 27717258
Br J Psychiatry. 2006 Aug;189:137-43
pubmed: 16880483
PLoS One. 2013 Oct 24;8(10):e76635
pubmed: 24204649
Schizophr Bull. 2016 Sep;42(5):1262-9
pubmed: 26884547
Curr Pharm Des. 2012;18(32):5093-104
pubmed: 22716138
Early Interv Psychiatry. 2019 Aug;13(4):798-804
pubmed: 29575691
CNS Spectr. 2021 Feb;26(1):84-91
pubmed: 32580808
Indian J Psychiatry. 2010 Apr;52(2):164-7
pubmed: 20838506
Br J Psychiatry Suppl. 1998;172(33):53-9
pubmed: 9764127
Front Psychiatry. 2019 Nov 20;10:851
pubmed: 31849723
Lancet Psychiatry. 2015 Mar;2(3):233-8
pubmed: 26359901
Psychiatry Res. 2015 Sep 30;229(1-2):70-4
pubmed: 26235479
Am J Psychiatry. 2018 Jan 1;175(1):37-46
pubmed: 28946763
Continuum (Minneap Minn). 2015 Jun;21(3 Behavioral Neurology and Neuropsychiatry):715-36
pubmed: 26039850
Schizophr Bull. 2019 Apr 25;45(3):610-619
pubmed: 30124959
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Schizophr Res. 1992 Mar;6(3):209-23
pubmed: 1571314
Psychopathology. 2019;52(5):304-315
pubmed: 31734668
Eur Arch Psychiatry Clin Neurosci. 2014 Mar;264(2):155-69
pubmed: 23835528
Int Rev Psychiatry. 2019 Aug - Sep;31(5-6):413-424
pubmed: 31456455
Schizophr Res. 2013 Aug;148(1-3):93-8
pubmed: 23746486
Addiction. 2017 Sep;112(9):1653-1657
pubmed: 28419656
Addiction. 2018 Jun;113(6):1077-1085
pubmed: 29377544
Br J Psychiatry. 2004 Jul;185:18-24
pubmed: 15231551
Psychiatry. 1996 Winter;59(4):371-80
pubmed: 9029658
Br J Psychiatry. 1995 May;166(5):654-9
pubmed: 7620753
Schizophr Res. 2005 Nov 1;79(1):85-93
pubmed: 16005612
BMC Psychiatry. 2020 Jan 7;20(1):8
pubmed: 31910829
Assessment. 2018 Jan;25(1):84-98
pubmed: 27178761
J Dual Diagn. 2020 Jan-Mar;16(1):22-42
pubmed: 31647377
Psychol Med. 2014 Jun;44(8):1577-90
pubmed: 24067164
Drug Alcohol Depend. 2021 Dec 1;229(Pt A):109118
pubmed: 34688166
Addiction. 2002 Dec;97 Suppl 1:4-15
pubmed: 12460125
World Psychiatry. 2017 Oct;16(3):251-265
pubmed: 28941089
Lancet Psychiatry. 2019 May;6(5):427-436
pubmed: 30902669
Hum Psychopharmacol. 2017 May;32(3):
pubmed: 28557062
Evid Based Ment Health. 2015 Aug;18(3):84
pubmed: 25979516
Arch Gen Psychiatry. 2005 Sep;62(9):975-83
pubmed: 16143729
Br J Psychiatry. 2009 Dec;195(6):488-91
pubmed: 19949195
Psychol Med. 2004 Feb;34(2):277-84
pubmed: 14982133
Eur Psychiatry. 2018 Jun;51:16-19
pubmed: 29510296
Schizophr Res. 2012 Dec;142(1-3):12-9
pubmed: 23025994
Pediatrics. 2017 Dec;140(6):
pubmed: 29109106
Brain Sci. 2020 Aug 05;10(8):
pubmed: 32764310
Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Aug;4(8):697-705
pubmed: 31171498
Schizophr Bull. 2016 May;42(3):619-25
pubmed: 26536902
Br J Psychiatry. 2014 Aug;205(2):88-94
pubmed: 25252316